Elanco Animal Health Incorporated $ELAN Shares Sold by Great Lakes Advisors LLC

Key Points

• Great Lakes Advisors LLC reduced its stake in Elanco Animal Health by 4.1%, owning approximately 973,234 shares valued at $10.2 million after selling 41,804 shares.
• Elanco's recent financial results showed earnings per share of $0.26, surpassing estimates and reflecting a 4.8% increase in quarterly revenue year-over-year.
• Several analysts have raised their price targets for Elanco, with UBS Group setting a new target of $19.00, while overall analyst consensus is a "Moderate Buy" rating with an average target price of $17.33.

Great Lakes Advisors LLC reduced its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 4.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 973,234 shares of the company's stock after selling 41,804 shares during the period. Great Lakes Advisors LLC owned about 0.20% of Elanco Animal Health worth $10,219,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in ELAN. Comerica Bank grew its holdings in Elanco Animal Health by 357.9% during the 4th quarter. Comerica Bank now owns 33,926 shares of the company's stock worth $411,000 after acquiring an additional 26,517 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Elanco Animal Health by 127.5% in the 4th quarter. Ameriprise Financial Inc. now owns 97,373 shares of the company's stock valued at $1,179,000 after buying an additional 54,581 shares during the period. Cetera Investment Advisers boosted its holdings in shares of Elanco Animal Health by 17.2% in the 4th quarter. Cetera Investment Advisers now owns 31,004 shares of the company's stock valued at $375,000 after buying an additional 4,553 shares during the period. CoreCap Advisors LLC acquired a new position in shares of Elanco Animal Health in the 4th quarter valued at about $29,000. Finally, Deutsche Bank AG boosted its holdings in shares of Elanco Animal Health by 7.3% in the 4th quarter. Deutsche Bank AG now owns 1,037,077 shares of the company's stock valued at $12,559,000 after buying an additional 70,690 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ELAN has been the subject of several research reports. Leerink Partners raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target for the company in a report on Thursday, July 17th. UBS Group lifted their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a report on Friday, August 8th. Leerink Partnrs raised shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 17th. Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Finally, Zacks Research lowered shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $17.33.

Elanco Animal Health Trading Up 3.2%

Shares of NYSE:ELAN opened at $19.02 on Tuesday. The company has a market cap of $9.45 billion, a PE ratio of 22.12, a P/E/G ratio of 3.42 and a beta of 1.62. The company's 50-day moving average price is $16.05 and its 200 day moving average price is $13.00. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $19.08. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.06. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. Elanco Animal Health's quarterly revenue was up 4.8% compared to the same quarter last year. During the same period last year, the firm posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.